#ASCO21: Takeda fleshes out case for oral EGFR drug with follow-up pivotal data in non-small cell lung cancer
Takeda is looking to carve out a major niche in non-small cell lung cancer with an oral TKI inhibitor targeting a rare but desperate patient …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
